Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG CLASS:

CD38 inhibitor

DRUG CLASS:

CD38 inhibitor

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Related drugs:

No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	isatuximab-irfc Sensitive: A1 - Approval isatuximab-irfc Sensitive : A1	isatuximab-irfc Sensitive: A1 - Approval isatuximab-irfc Sensitive : A1
No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	lenalidomide + daratumumab and hyaluronidase-fihj Sensitive: A1 - Approval lenalidomide + daratumumab and hyaluronidase-fihj Sensitive : A1	lenalidomide + daratumumab and hyaluronidase-fihj Sensitive: A1 - Approval lenalidomide + daratumumab and hyaluronidase-fihj Sensitive : A1
No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	lenalidomide + daratumumab Sensitive: A1 - Approval lenalidomide + daratumumab Sensitive : A1	lenalidomide + daratumumab Sensitive: A1 - Approval lenalidomide + daratumumab Sensitive : A1
No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	daratumumab and hyaluronidase-fihj Sensitive: A1 - Approval daratumumab and hyaluronidase-fihj Sensitive : A1	daratumumab and hyaluronidase-fihj Sensitive: A1 - Approval daratumumab and hyaluronidase-fihj Sensitive : A1
No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	pomalidomide + isatuximab-irfc Sensitive: A1 - Approval pomalidomide + isatuximab-irfc Sensitive : A1	pomalidomide + isatuximab-irfc Sensitive: A1 - Approval pomalidomide + isatuximab-irfc Sensitive : A1
No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	daratumumab + pomalidomide Sensitive: A1 - Approval daratumumab + pomalidomide Sensitive : A1	daratumumab + pomalidomide Sensitive: A1 - Approval daratumumab + pomalidomide Sensitive : A1
No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	daratumumab Sensitive: A1 - Approval daratumumab Sensitive : A1	daratumumab Sensitive: A1 - Approval daratumumab Sensitive : A1
No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	daratumumab + thalidomide Sensitive: A1 - Approval daratumumab + thalidomide Sensitive : A1	daratumumab + thalidomide Sensitive: A1 - Approval daratumumab + thalidomide Sensitive : A1
No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	thalidomide + daratumumab and hyaluronidase-fihj Sensitive: A1 - Approval thalidomide + daratumumab and hyaluronidase-fihj Sensitive : A1	thalidomide + daratumumab and hyaluronidase-fihj Sensitive: A1 - Approval thalidomide + daratumumab and hyaluronidase-fihj Sensitive : A1
No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	pomalidomide + daratumumab and hyaluronidase-fihj Sensitive: A1 - Approval pomalidomide + daratumumab and hyaluronidase-fihj Sensitive : A1	pomalidomide + daratumumab and hyaluronidase-fihj Sensitive: A1 - Approval pomalidomide + daratumumab and hyaluronidase-fihj Sensitive : A1
No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	selinexor + daratumumab Sensitive: A2 - Guideline selinexor + daratumumab Sensitive : A2	selinexor + daratumumab Sensitive: A2 - Guideline selinexor + daratumumab Sensitive : A2
No biomarker	B Acute Lymphoblastic Leukemia	No biomarker	B Acute Lymphoblastic Leukemia	daratumumab Sensitive: A2 - Guideline daratumumab Sensitive : A2	daratumumab Sensitive: A2 - Guideline daratumumab Sensitive : A2